FDA's Alzheimer's guidance could boost CRO opportunities

Amid a spate of Phase III disasters for Alzheimer's drugs, the FDA is joining the industry chorus and telling drugmakers that they'd be better served by going after early-stage patients who have yet to experience significant brain damage. The high-profile failures of late-stage-targeting drugs such as bapineuzumab and solanezumab are likely to motivate biotechs to shift their focus, and a swell of new programs means a big opportunity for CNS-focused CROs to nab development deals. More

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.